Helix BioPharma Corp HBPCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.15
- Day Range
- $0.14–0.14
- 52-Week Range
- $0.14–0.15
- Bid/Ask
- $0.22 / $0.74
- Market Cap
- $29.84 Mil
- Volume/Avg
- 287 / 8,766
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 7
- Website
- https://www.helixbiopharma.com
Valuation
|
Metric
|
HBPCF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HBPCF
|
|---|---|
Quick Ratio | 1.34 |
Current Ratio | 1.46 |
Interest Coverage | −459.08 |
Quick Ratio
HBPCF
Profitability
|
Metric
|
HBPCF
|
|---|---|
Return on Assets (Normalized) | −214.33% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,316.83% |
Return on Assets
HBPCF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cbvdfmhzb | Sfdf | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bqhbtjcbc | Jvfksj | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nnwbzgxk | Lscqkbf | $97.8 Bil | |
MRNA
| Moderna Inc | Lytcztf | Pgrn | $38.8 Bil | |
ARGX
| argenx SE ADR | Vwgdpnyl | Ywc | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Bfhywlsc | Ywkn | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gfqpgmyg | Pnysrt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mcqpmrlg | Xrgwb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dmpfcnfv | Yynlc | $12.5 Bil | |
INCY
| Incyte Corp | Yjlwtkbn | Ypftsv | $11.5 Bil |